PKTX PR News..January 15, 2009 11:02 AM Eastern Time
ProtoKinetix’ Joint Venture to Produce Exclusive Combination AAGP™ and Co-enzyme Q10 Skin/Health Care Product Line
VANCOUVER--(BUSINESS WIRE)--Ross Senior, President and CEO of ProtoKinetix Inc. (PKTX), announces the formation of a Joint Venture with Zymes LLC to commercialize a unique new product line. Zymes is a world leader in the production of high quality Co-enzyme Q10, a well recognized and potent anti-oxidant. Zymes’ Co-founder and Chief Scientific Officer, Dr. Bruce Lipshutz, has patented a method for producing water soluble CoQ10 (The Lipshutz Method) which has been proven to increase the absorption into cells and tissues for protection and repair. This Joint Venture will combine the knowledge and expertise of two world renowned sciences from France (Dr. Geraldine Deliencourt) and the United States (Prof. Bruce Lipshutz, U of C, Santa Barbara).
Over the last few years extensive tests by PKTX subjected skin cells to harmful oxidative stresses of ultra violet radiation and hydrogen peroxide. The tests showed AAGP™ to be a powerful anti-oxidant, however the combination of these two molecules (AAGP™ and CoQ10) provided significantly greater protection from the harmful oxidative stresses than could otherwise be attained from either molecule acting individually. ProtoKinetix’ news release of January 26, 2006 provides a summary of the dramatic results achieved combining these two molecules for cell and tissue protection. UV radiation and oxidation damage cells, tissues and organs and are major contributors to aging of the skin.
The Joint Venture is founded on the unique combination of the molecular structures, bioactivities and health care attributes of PKTX’ AAGP™ and Zymes’ CoQ10. In addition to skin care, other targeted applications include stem cell preservation and survival, ischemia, reperfusion injury and wound healing. The diversity of applications underscores the value of the AAGP™ family of molecules.
Ross Senior says, “We are extremely pleased to partner with Zymes and are confident about the success of the venture and the benefits for our shareholders.”
